P/E ratio for Bristol-Myers Squibb (BMY)
P/E ratio as of July 2025 (TTM): 17.9
According to Bristol-Myers Squibb's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 17.9328. At the end of 2024 the company had a P/E ratio of -12.8.
P/E ratio history for Bristol-Myers Squibb from 2001 to 2025
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2024 | -12.8 | -196.76% |
| 2023 | 13.2 | -45.23% |
| 2022 | 24.1 | 22.82% |
| 2021 | 19.7 | -226.77% |
| 2020 | -15.5 | -153.28% |
| 2019 | 29.1 | 69.66% |
| 2018 | 17.2 | |
| 2016 | 21.9 | -69.14% |
| 2015 | 70.9 | 45.37% |
| 2014 | 48.8 | 43.19% |
| 2013 | 34.1 | 21.27% |
| 2012 | 28.1 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Pfizer PFE | 17.7 | -1.39% | 🇺🇸 USA |
 Merck MRK | 11.8 | -34.09% | 🇺🇸 USA |
 Eli Lilly LLY | 61.6 | 243.67% | 🇺🇸 USA |
 Novartis NVS | 17.8 | -0.68% | 🇨🇭 Switzerland |
 Sanofi SNY | 17.1 | -4.71% | 🇫🇷 France |
 AstraZeneca AZN | 27.6 | 54.18% | 🇬🇧 UK |
 Johnson & Johnson JNJ | 18.0 | 0.23% | 🇺🇸 USA |
 AbbVie ABBV | 81.2 | 352.73% | 🇺🇸 USA |
 Amgen AMGN | 27.0 | 50.51% | 🇺🇸 USA |
 Biogen BIIB | 12.7 | -29.37% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.